Jagsonpal Pharmaceuticals Limited announced unaudited standalone earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported net sales/income from operations was INR 268.965 million against INR 401.102 million a year ago. Loss from operations before other income, finance cost and exceptional items was INR 41.559 million against income of INR 17.501 million a year ago. Loss from ordinary activities before tax was INR 42.207 million against income of INR 8.017 million a year ago. Net loss from ordinary activities after tax was INR 42.207 million against income of INR 6.414 million a year ago. Diluted loss per share before extraordinary items was INR 1.61 against income of INR 0.24 a year ago.